This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.
Age ≥ 20 years at the time of consent.
Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
Presence of activating EGFR mutation (exon 19 deletion or L858R).
Stage IV (metastatic) NSCLC at initial diagnosis.
Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy.
Extensive, unresectable metastatic disease not amenable to local therapy.
Untreated or clinically unstable brain metastases.
Known contraindications to surgery or radiotherapy.